-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 6.4%
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 6.4%
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating)'s share price traded down 6.4% during trading on Tuesday . The stock traded as low as $0.98 and last traded at $1.02. 300,374 shares traded hands during trading, a decline of 91% from the average session volume of 3,483,830 shares. The stock had previously closed at $1.09.
Bright Minds Biosciences Stock Down 6.4 %
The company's 50 day moving average price is $1.03 and its 200-day moving average price is $1.14.
Get Bright Minds Biosciences alerts:Hedge Funds Weigh In On Bright Minds Biosciences
An institutional investor recently bought a new position in Bright Minds Biosciences stock. Jane Street Group LLC bought a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
Bright Minds Biosciences Company Profile
(Get Rating)Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Featured Articles
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating)'s share price traded down 6.4% during trading on Tuesday . The stock traded as low as $0.98 and last traded at $1.02. 300,374 shares traded hands during trading, a decline of 91% from the average session volume of 3,483,830 shares. The stock had previously closed at $1.09.
納斯達克週二盤中股價下跌6.4%，盤中一度跌至0.98美元，最新報1.02美元。300,374股股票全天成交，較當日平均成交量3,483,830股下跌91%。該股此前收盤報1.09美元。
Bright Minds Biosciences Stock Down 6.4 %
光明之心生物科學公司股價下跌6.4%
The company's 50 day moving average price is $1.03 and its 200-day moving average price is $1.14.
該公司的50日移動均線價格為1.03美元，其200日移動均線價格為1.14美元。
Hedge Funds Weigh In On Bright Minds Biosciences
對沖基金對Bright Minds生物科學的看法
An institutional investor recently bought a new position in Bright Minds Biosciences stock. Jane Street Group LLC bought a new position in Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
一家機構投資者最近買入了Bright Minds Biosciences股票的新頭寸。建恩街集團(Jane Street Group LLC)提交給美國證券交易委員會(Securities&Exchange Commission)的最新Form 13F檔案顯示，該公司在第一季度購買了Bright Minds Biosciences Inc.(納斯達克：毒品獲得評級)的一個新頭寸。該公司購買了24,701股該公司股票，價值約37,000美元。在最近一次報告期結束時，建恩街集團擁有Bright Minds Biosciences約0.21%的股份。機構投資者持有該公司4.03%的股份。
Bright Minds Biosciences Company Profile
Bright Minds生物科學公司簡介
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家臨床前生物科學公司，開發5-羥色胺(5-HT)藥物，以改善嚴重和改變生活的疾病患者的生活。該公司的選擇性5-羥色胺受體激動劑組合包括5-HT2C、5-HT2A和5-HT2C/A，用於治療癲癇、疼痛和神經精神病學。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
- Should The Bancorp Make Your Small-Cap Watchlist for 2023?
- 3 Consumer Cyclical Stocks With Good Momentum
- Could Pinduoduo Be the Best Chinese Stock to Own?
- 3 Big Box Retail Bets for the Holidays
- 免費獲取StockNews.com關於Bright Minds生物科學(藥物)的研究報告
- Ulta發佈美好的財年前景，但這只股票現在是買入的嗎？
- Bancorp應該入選2023年小盤股觀察名單嗎？
- 3勢頭良好的消費週期股
- 拼多多可能是最值得持有的中國股票嗎？
- 節假日的三大零售賭注
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bright Minds Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧